Karyopharm Therapeutics | KPTI - Ebitda


Karyopharm Therapeutics reported $-26.2M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Abbott USD 3.09B 44M Sep/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Incyte USD 506.92M 74.6M Sep/2025
J&J USD 9.52B 389M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.88B 290M Sep/2025
Novartis USD 5.84B 235M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Takeda JPY 448.13B 173.98B Dec/2025
Tectonic Therapeutic USD -13.48M 5.73M Dec/2024
TG Therapeutics USD 37.7M 25.41M Jun/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Xencor USD -30.52M 6.39M Jun/2025